UCB S.A.: Lupus Erythematosus, Systemic trials

The registry lists 20 Lupus Erythematosus, Systemic studies with UCB S.A. as lead sponsor. 3 are open to participants now and 5 have results posted.

Phase 1 5Phase 2 7Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Study of Cizutamig in Systemic Lupus ErythematosusRecruitingNCT07215663Phase 1
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusRecruitingNCT06617325Phase 3
• A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus ErythematosusEnrolling by invitationNCT04976322Phase 3
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus ErythematosusCompletedNCT04294667Phase 3Results posted
• A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus ErythematosusCompletedNCT02804763Phase 2Results posted
• Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus ErythematosusCompletedNCT01408576Phase 3Results posted
• Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus ErythematosusCompletedNCT01262365Phase 3Results posted
• Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)CompletedNCT01261793Phase 3Results posted
• Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the BloodCompletedNCT02306629Phase 1
• Safety Study of CDP7657 in Patients With Systemic Lupus ErythematosusCompletedNCT01764594Phase 1
• Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) SubjectsCompletedNCT01534403Phase 2
• Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)CompletedNCT01449071Phase 1/2
• Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)CompletedNCT01093911Phase 1
• Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active DiseaseCompletedNCT00660881Phase 2
• Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active DiseaseCompletedNCT00624351Phase 2
• Study of Epratuzumab in Systemic Lupus ErythematosusCompletedNCT00383513Phase 2
• Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)TerminatedNCT00383214Phase 3
• Study of Epratuzumab in Systemic Lupus ErythematosusWithdrawnNCT00382837Phase 3
• Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)TerminatedNCT00113971Phase 2
• Study of Epratuzumab in Systemic Lupus ErythematosusTerminatedNCT00111306Phase 3